【レポートの概要（一部）】
1. Report Overview
1.1 The Alzheimer’s Disease Therapeutics and Diagnostics Market Overview
1.2 Alzheimer’s Disease Therapeutics and Diagnostics Market Forecast 2014-2024
1.3 Why You Should Read This Report
1.4 How This Report Delivers
1.5 Key Questions Answered by This Analytical Report
1.6 Who is This Report For?
1.7 Methodology
1.8 Frequently Asked Questions (FAQ)
1.9 Associated Reports
1.10 About Visiongain
2. Alzheimer’s Disease: An Introduction
2.1 Neurodegenerative Diseases
2.1.1 What is Alzheimer’s Disease?
2.1.2 What Causes Alzheimer’s Disease?
2.1.2.1 Alzheimer’s Disease: Type 3 Diabetes?
2.1.3 Management of Alzheimer’s Disease
2.1.4 The Socio-Economic Impact of Alzheimer’s Disease
2.1.5 Diagnosis of Alzheimer’s Disease
3. Alzheimer’s Disease Therapeutics and Diagnostics Market 2014-2024
3.1 Alzheimer’s Disease Therapeutics and Diagnostics Market, 2013
3.2 Alzheimer’s Disease Therapeutics and Diagnostics Market Forecast, 2014-2024
3.2.1 The Market Has Been Left Exposed to Intensified Generic Competition
3.2.2 Healthcare Costs for Alzheimer’s Disease Will Surpass All Other Medical Expenses
3.2.3 New Diagnostics and Drugs Regulatory Guidelines Will Lower the Barriers to Entry
3.3 Drivers and Restraints
4. The Alzheimer’s Disease Drugs Market, 2014-2024
4.1 Current Approaches and Unmet Needs in the Treatment of Alzheimer’s disease
4.2 The Alzheimer’s Disease Drugs Market, 2013
4.3 Changing Market Shares of the Leading Alzheimer’s Disease Drugs, 2014-2024
4.4 The Alzheimer’s Disease Drugs Market Forecast 2014-2024
4.5 Namenda
4.5.1 Namenda Sales Forecast, 2014-2024
4.6 Aricept
4.6.1 Aricept Sales Forecast, 2014-2024
4.7 Exelon
4.7.1 Exelon Sales Forecast, 2014-2024
4.8 Alzheimer’s Disease Drugs Pipeline, 2014
4.8.1 Recent High-Profile Failures of Clinical Trials for Alzheimer’s Disease Drug Candidates
4.8.1.1 Solanezumab (Eli Lilly)
4.8.1.2 LY-2886721 (Eli Lilly)
4.8.1.3 GSK2647544 (GSK)
4.8.1.4 Bapineuzumab (Elan/J&J/Pfizer)
4.8.1.5 Gammagard (Baxter)
4.9 FDA to Relax Rules for the Approval of Alzheimer’s Drugs
4.10 Will Novel Drug Development Strategies Prove Successful?
4.11 Promising Therapies in the Alzheimer’s Disease Drugs Pipeline, 2013
4.11.1 Solanezumab (Eli Lilly)
4.11.1.1Solanezumab Sales Forecast 2014-2024
4.11.2 Gantenerumab (Roche)
4.11.2.1The Gantenerumab Pipeline Forecast, 2014-2024
4.11.3 MK-8931 (Merck)
4.11.3.1 The MK-8931 Pipeline Forecast, 2014-2024
4.11.4 TTP488 (TransTechPharma)
4.11.5 LMTX (TauRx)
4.11.6 EVP-6124 (Forum Pharmaceuticals)
4.12 Deep Brain Stimulation (Functional Neuromodulation)
4.13 Leading Companies in the Alzheimer’s Disease Drugs Market, 2013
4.13.1 Pfizer, Inc
4.13.1.1Sales and Recent Performance Analysis, 2013
4.13.1.2 Pfizer: Aricept
4.13.1.3 Pfizer: R&D Capabilities and Alzheimer’s Disease Drug Candidates
4.13.2 Eisai
4.13.2.1 Sales and Recent Performance Analysis, 2013
4.13.2.2 Eisai: Aricept
4.13.2.3 Eisai: R&D Capabilities and Alzheimer’s Disease Drug Candidates
4.13.2.4 Collaboration with Biogen
4.13.2.5 Partnership with GE Healthcare for Diagnostic Development
4.13.3 Forest Laboratories (Acquired by Actavis)
4.13.3.1Acquisition by Actavis
4.13.3.2 Forest: Namenda
4.13.3.3 Namenda’s Sales and Recent Performance Analysis, 2013
4.13.4 Lundbeck A/S
4.13.4.1 Sales and Recent Performance Analysis, 2013
4.13.4.2 Lundbeck: R&D Capabilities
4.13.4.3 Lundbeck’s Alzheimer’s Disease Drug Pipeline
4.13.4.4 Lundbeck: Ebixa
4.13.5 Daiichi Sankyo
4.13.5.1 Financial Sales and Recent Performance, 2013
4.13.5.2 Daiichi Sankyo: Memary
4.13.6 Novartis AG
4.13.6.1 Sales and Recent Performance Analysis, 2013
4.13.6.2 Novartis: Exelon
4.13.6.3 eHealth Programme Delivering Innovation
4.13.6.4 Novartis: Alzheimer’s Disease Drug Pipeline
4.13.7 TauRx
4.13.7.1 Partnership with Bayer Schering Pharma AG
4.13.8Transtech Pharma
4.13.8.1TTP Translational Technology
4.13.8.2 TranstechPharma: Alzheimer’s Disease Pipeline Portfolio
5. The Alzheimer’s Disease Diagnostics Market, 2014-2024
5.1 There is Still a Strong Market Need for Effective Diagnosis
5.2 The Alzheimer’s Disease Diagnostics Market, 2013
5.3 Changing Market Shares of Leading Alzheimer’s Diagnostic Markets, 2014-2024
5.4 The Alzheimer’s Diagnostics Market, 2014-2024
5.5 New Criteria and Guidelines to Diagnose Alzheimer’s Disease
5.6 Biomarkers for Alzheimer’s Disease
5.6.1 Leading Companies Pursuing Novel Biomarker Development Strategies
5.7 Alzheimer’s Disease: Advances in Diagnostic Imaging Technologies
5.7.1 Structural Imaging
5.7.2 Functional Imaging
5.7.3 Molecular Imaging Technologies
5.7.3.1 Pittsburgh Compound B (PIB) (GE Healthcare)
5.7.3.2 Florbetapir F18 (18F-AV-45) (Eli Lilly)
5.7.3.3 Flutemetamol (GE Healthcare)
5.7.3.4 Florbetaben (Piramal Imaging)
5.8 Other Alzheimer’s Diagnostics in Development
5.8.1 CSF Proteins
5.8.2 Blood Based Biomarkers for Alzheimer’s Disease
5.8.3 Genetic Risk Profiling
5.8.4 Eye Tests
5.9 Leading Companies in the Alzheimer’s Disease Diagnostics Market, 2014
5.9.1 Eli Lilly
5.9.1.1 Recent Performance and Sales Analysis, 2013
5.9.1.2 Alzheimer’s Disease Research Effort
5.9.1.3 Solanezumab
5.9.1.4 Amyvid (Florbetapir F18)
5.9.1.5 Amyvid Receives Marketing Authorization from the European Commission
5.9.1.6 LY-2886721: Terminated Drug
5.9.1.7 N3pG-AB mAb:Phase I
5.9.1.8 Eli Lilly Acquires Novel Tau Tangle Diagnostic Programme
5.9.2 Amarantus BioScience Holdings, Inc.
5.9.2.1 Recent Performance and Sales Analysis, 2013
5.9.2.2 LymPro
5.9.2.3 Intellectual Property Acquisitions
5.9.3 Piramal Enterprises
5.9.3.1Piramal Imaging SA
5.9.3.2 U.S. and EMA Approval of Florbetaben
5.9.3.3 Manufacturing and Distribution Agreements
5.9.4 GE Healthcare
5.9.4.1 GE’s Commitment to Imaging Research in the Alzheimer’s Field
5.9.4.2 Regulatory Approval of Flutemetamol
5.9.4.3 Licensing Agreements for Flutemetamol
5.9.5 Navidea
5.9.5.1 NAV4694 (Fluorine-18)
5.9.5.2 Collaboration Agreements
5.9.5.3 NAV4694 Clinical Development
5.9.6 Diagenic
5.9.6.1 Organisational Restructuring
6. The Leading National Markets, 2014-2024
6.1 Regional Breakdown of the Global Alzheimer’s Disease Therapeutics and Diagnostic Market, 2013
6.1.1 The US and Europe Represent More than 70% of the Total Market
6.2 The Global Alzheimer’s Disease Therapeutics and Diagnostics Market: Regional Forecast, 2014-2024
6.3 Changing Market Shares of Leading National Markets 2014-2024
6.4 The US Alzheimer’s Disease Therapeutics and Diagnostics Market, 2014-2024
6.4.1 One in Eight Over the Age of 65 has AD in the US
6.4.2 The US Will Remain the Largest Market Over the Forecast Period
6.5 The European Alzheimer’s Disease Therapeutics and Diagnostics Market, 2014-2024
6.5.1 The German Alzheimer’s Disease Therapeutics and Diagnostics Market Forecast, 2014-2024
6.5.2 The French Alzheimer’s Disease Therapeutics and Diagnostics Market Forecast,
2014-2024
6.5.3 The UK Alzheimer’s Disease Therapeutics and Diagnostics Market Forecast, 2014-
2024
6.5.4 The Spanish Alzheimer’s Disease Therapeutics and Diagnostics Market Forecast, #
2014-2024
6.5.5 The Italian Alzheimer’s Disease Therapeutics and Diagnostics Market Forecast,
2014-2024
6.5.6 The Rest of Europe Alzheimer’s Disease Therapeutics and Diagnostics Market
Forecast, 2014-2024
6.6 The Japanese Alzheimer’s Disease Therapeutics and Diagnostics Market Forecast, 2014-2024
6.7 The Chinese Alzheimer’s Disease Therapeutics and Diagnostics Market Forecast, 2014-2024
6.8 The Indian Alzheimer’s Disease Therapeutics and Diagnostics Market Forecast, 2014-2024
6.9 The Brazilian Alzheimer’s Disease Therapeutics and Diagnostics Market Forecast, 2014-2024
6.10 The Russian Alzheimer’s Disease Therapeutics and Diagnostics Market Forecast, 2014-2024
6.11 The Rest of the World Alzheimer’s Disease Therapeutics and Diagnostics Market Forecast, 2014-2024
7. Qualitative Analysis of the Alzheimer’s Disease Therapeutics and Diagnostics Market, 2014-2024
7.1 SWOT Analysis
7.2 Strengths
7.2.1 Alzheimer’s Disease is a High Profile Disease
7.2.2 Expanding Patient Population
7.2.3 Strong R&D Pipeline in Both Sectors of the Market
7.3 Weaknesses
7.3.1 Current Drugs Only Treat the Symptoms of Alzheimer’s Disease
7.3.2 Recent Failures of Promising Drug Candidates in Clinical Trials
7.3.3 Poor Macroeconomic Conditions in Key Regions of the Market
7.4. Opportunities
7.4.1 Regulations Seeking Improved Standards of Alzheimer’s Disease Drug Development
7.4.2 Neurodegenerative Diseases Have Strong R&D
7.4.3 Emerging Markets Will Help Drive the Market
7.4.4 Advances in Diagnostic Technologies Will Improve Drug Market Penetration
7.5 Threats
7.5.1 Patent Expiries Will Lead to Further Generic Competition
7.5.2 New AD Therapies Face Political, Commercial and Social Pressures
7.6 Porter’s Five Force Analysis
7.6.1 Rivalry Among Competitors
7.6.2 Threats of New Entrants
7.6.3 Powers of Suppliers
7.6.4 Bargaining Power of Buyers
7.6.5 Threat of Substitutes
8. Expert Opinions
8.1 Dr Simon Ridley, Head of Research, Alzheimer’s Research UK
8.1.1 Alzheimer’s Treatment in Late Stage Development
8.1.2 The Benefits of Alzheimer’s Diagnosis: A Future Prospect
8.1.3 Alzheimer’s and its Relationship with Other Diseases
8.1.4 Strategies to Incentivise Alzheimer’s Research and Investment
8.2 David Hanlon, Director of Business Development and Strategic Collaborations, Quanterix
8.2.1 Ultra Sensitive Automated Immunoassay Platform for Alzheimer’s
8.2.2 Alzheimer’s Disease Blood-based Biomarkers
8.2.3 Research Based Setting of the Simoa Technology
8.2.4 Quanterix: Alzheimer’s Partners and Collaborations
8.3 Elizabeth Edgerly, Ph.D., Chief Program Officer, The Alzheimer’s Association Northern California and Northern Nevada
8.3.1 Alzheimer’s Severe Under diagnosis
8.3.2 Novel Biomarkers: Critical for Alzheimer’s Diagnosis
8.3.3 Alzheimer’s Treatment Paradigm: Needs to be More Universally Effective
8.3.4 A Push to Improve the Success of Alzheimer’s Research
8.3.5 Alzheimer’s Treatment: The Greatest Challenge
9. Conclusions
9.1 Novel Diagnostic Technologies Will Emerge First and Then the Disease Modifying Drugs
9.2 Disease Modifying Drugs Will Transform the Declining Alzheimer’s Market
9.3 Demographics Will Help Drive the Market Over the Forecast Period
9.4 Medicines and Diagnostic Tests for Alzheimer’s Disease Hold Great Potential from 2014 to 2024
【レポート販売概要】
■ タイトル：世界のアルツハイマー病治療薬・診断市場予測■ 英文：ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET FORECAST 2014-2024
Opportunities for Leading Companies
■ 発行日：2014年8月
■ 調査会社：visiongain
■ 商品コード：VISG409044
■ 調査対象地域：グローバル
- ランニング用品の世界市場：ランニングフットウェア、ランニングウェア、ランニングアクセサリー、フィットネス・トラッカーAbout the Running Gear Market The growing awareness of the benefits of being healthy and maintaining physical fitness among the global population is aiding in increasing the popularity of running, as it is considered as one of the best forms of exercise to enhance fitness. Marathons are increasingly becoming popular as well, with participation not restricted to only professional athletes. The incr …
- 民間航空機ウインドー及びフロントガラスの世界市場2016-2020About Windows in Aircraft Passenger Cabins Windows in aircraft passenger cabins are smaller in size to maximize the areas of the hull between them and to increase the mechanical strength of the airframe. From a technical point of view, an aircraft fuselage would be much stronger if it could completely remove cut-outs for windows and windshields. In the 1970s, there were incidents in several De Hav …
- 酸化エチレン(EO)の世界市場動向及び予測2015The present report is an essential resource for a one looking for detailed information on the world ethylene oxide market. The report covers data on global, regional and national markets including present and future trends for supply and demand, prices, and downstream industries. In addition to the analytical part, the report provides a range of tables and figures which all together give a true in …
- BRIC（ブラジル/ロシア/インド/中国）の腹腔鏡市場（～2020）BRIC Laparoscopes Market Outlook to 2020 Summary GlobalData’s new report, "BRIC Laparoscopes Market Outlook to 2020", provides key market data on the BRIC Laparoscopes market. The report provides value, in millions of US dollars, volume (in units) and average prices (in US dollars) within market segments - Video Laparoscopes (Rigid Tip Video Laparoscopes and Flexible Tip Video Laparoscopes), Robot …
- 中国の移動補助・運搬機器市場見通し（～2021）China Mobility Aids and Transportation Equipment Market Outlook to 2021 Summary GlobalData’s new report, "China Mobility Aids and Transportation Equipment Market Outlook to 2021", provides key market data on the China Mobility Aids and Transportation Equipment market. The report provides value, in millions of US dollars, volume (in units) and average price data (in US dollars), within market segme …
- 医薬品製造受託（CMO）サービスの世界市場Contracted drug production – discover trends and segments with highest revenue potential Where’s outsourced pharma manufacturing heading? Visiongain’s updated study predicts that industry’s revenues from 2015. There you find potentials for sales growth, also understanding trends, technologies for drugs, clients’ needs and opportunities. That new report gives you revenue forecasts to 2025 at overal …
- 2014年戦略提言：Adenovirusの診断検査市場The report presents a detailed analysis of the Adenovirus diagnostics market in the US, Europe (France, Germany, Italy, Spain, UK) and Japan. Current scientific views on the Adenovirus definition, epidemiology and etiology are reviewed. The report provides the 5-year test volume and sales forecasts by country for the following market segments: - Hospitals - Co …
- M2Mサービスの世界市場：移動通信、固定通信、衛星通信About Global M2M Services Market M2M is a technology that enables communication through wired and wireless technology. The exchange of information takes place between machines and devices or sensors. Most of the wireless M2M applications It is used in various industries such as healthcare, automotive, oil and gas, transportation, public safety, and retail for smooth functioning of operations, enha …
- 脳・組織用酸素測定機器の世界市場2016-2020About the Cerebral and Tissue Oximetry Devices Market Cerebral and tissue oximeters help physicians obtain non-invasive, continuous measures of cerebral oxygenation levels in the cerebral tissues. These near-infrared spectroscopy technology-based devices consist of an oximeter probe connected to a cerebral oximeter monitor via a cable. The oximeter probe is placed on the forehead, at an area with …
- リキッドバイオプシーの世界市場2017-2021About Liquid Biopsy Like prostate cancer, other cancer cases such as lung cancer and breast cancer are increasing. To treat the disease at its early stage, liquid biopsies are performed, which helps in the detection of cancer. An increasing number of cancer cases will increase the need for liquid biopsy in the market. The skilled lab technicians are required to handle liquid biopsy systems such as …
- ゴルフウェアの世界市場：メンズゴルフウェア、レディースゴルフウェア、キッズゴルフウェアAbout golf apparel Golf is a popular sport and is highly popular among business individuals and amateur players. The game as apart from being an exercise also facilitates socializing. The game has relatively little physical requirement in comparison to other form of exercise and sports. Golf has not featured in the Olympics since 1904; however, with rapid expansion and globalization of the sport, …
- ジン（Gin/スピリッツ）の世界市場About Gin Gin is a spirit, which is made from juniper berries. Increase in demand among the millennial population in the US, growing demand for premium gin, and increased marketing and promotions by vendors are some of the factors that have driven the consumption of gin. Gin is classified into three types based on the method of production: pot distilled gin, column distilled gin, and compound gin. …
- 世界のオンライン広告市場状況：検索広告、ディスプレイ広告、モバイル広告、RTB、SNS、ビデオ広告n/a
- 缶詰食品の世界市場2016-2020About Canned Food Canned food products refer to food items that are processed, preserved, and packed into airtight metal containers. Canned food products find high demand globally because they require less time to cook, less storage space, and have a longer shelf life than fresh food. With consumer lifestyles becoming increasingly work-oriented and, consequently, hectic, people have less time to c …
- 切断装置・付属品・消耗品の世界市場：装置（手動、機械式）、付属品（ガス調整器、ガスフィルタ）、消耗品（シールド、オキシ燃料ガス）、技術（プラズマ、酸素燃焼、レーザー）MarketsandMarkets projects that the market for cutting equipment, accessories, and consumables will grow from 6.67 USD Billion in 2016 to 8.27 USD Billion by 2021, at a CAGR of 4.40%. This market is growing due to increasing infrastructure and construction activities, manufacturing of automobiles, public expenditure from governments and production of crude steel. Rising per capita income of the mi …
